Eli Lilly (LLY) Total Non-Current Liabilities (2009 - 2026)

Eli Lilly has reported Total Non-Current Liabilities for 18 years, with the latest figure at $48.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 12.12% year-over-year to $48.7 billion; the trailing twelve-month figure through Mar 2026 stood at $48.7 billion (up 12.12% YoY), and the FY2025 full-year result was $50.7 billion, up 40.61% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $48.7 billion, down from $50.7 billion in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $50.9 billion in Q3 2025, with the low at $21.6 billion in Q4 2022.
• Historically, Total Non-Current Liabilities has averaged $33.2 billion across 5 years, with a median of $31.1 billion in 2024.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities retreated 18.49% — and 2024, when it jumped 48.77%.
• Eli Lilly's Total Non-Current Liabilities stood at $21.6 billion in 2022, then increased by 19.81% to $25.8 billion in 2023, then jumped by 39.53% to $36.1 billion in 2024, then soared by 40.61% to $50.7 billion in 2025, then declined by 3.88% to $48.7 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $48.7 billion (Q1 2026), $50.7 billion (Q4 2025), and $50.9 billion (Q3 2025), per Business Quant data.